AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate t...
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate to fall short of the bar set by Ascendis Pharma’s Yorvipath.